Privacy Policy

Incyte Corporation ("Incyte") is committed to maintaining the privacy and security of your personally identifiable information collected through this Web site. This Privacy Policy sets forth Incyte’s information collection and dissemination practices in connection with the Web site and applies solely to the information collected through the Web site. This Privacy Policy does not address personally identifiable information that you provide to us in other contexts. By using the Web site, you signify your acceptance of this Privacy Policy.

Personally Identifiable Information
With respect to the Web site, Incyte will only collect, store or use personally identifiable information (that is, any information by which you can be identified, such as name, address, e-mail address, and telephone number, which we refer to as "Your Information"), when it is voluntarily submitted to us. You have the option not to provide any of Your Information to us. If you do provide Your Information to us, Your Information may be used to fulfill your request for information, to provide you with other information or services, to market future products and services which we think may be of interest to you, to communicate with you for other purposes, to respond to requests you may make of us, and from time to time, we may refer to Your Information to better understand your needs and how we can improve the Web site's services and we may use Your Information within the company for performing marketing studies or other analyses. We will not sell Your Information to any other company or organization. We may share Your Information with other companies or organizations that work with, or on behalf of, Incyte to provide products and services, but subject to limitations on their use or disclosure.

If you choose not to provide the information we may request, you can still visit most of the Web site, but you may be unable to access certain options and services. In general, you can visit the Web site without telling us who you are or revealing any personal information about yourself. We may track the total number of visitors to our site, the number of visitors to each page of our site, and the domain names of our visitors' Internet service providers and analyze this data for trends and statistics, but the individual user remains anonymous. From time to time we may share such aggregated data with third parties assisting us in market research.

You may update Your Information and opt out of receiving certain communications or have us stop contacting you by accessing your registration or profile. You may also opt out of receiving e-mails and other communications from us by using the features or other communication means contained in e-mails sent to you. Such requests will be subject to any applicable legal and ethical reporting or document filing or retention obligations.

Use of Cookies
We may use the data we obtain through the use of cookies (small data files that a Web site transfers to your browser to store on your computer when you access a Web site) to customize your site experience by anticipating the information and services that may be of interest to you. We may also analyze the information collected with cookie technology to help us improve the functioning of the Web site by monitoring traffic in popular areas and to modify the services and information we provide to meet customer demand. We may link the data available to us through the use of cookies to the personally identifiable information and health-related information that you may choose to provide elsewhere on the Web site. We use the information we collect through the use of cookies for our business purposes, including operation of the Web site. To disable or limit the use of cookies, please refer to the options provided by your browser. If you do so, however, some portions of the Web site may not work properly.

Release in Limited Circumstances
In certain limited circumstances, Incyte may be required to release Your Information in response to a court order, subpoena, search warrant, law, or regulation. We also reserve the right to cooperate with law enforcement authorities in investigating and prosecuting users who violate our rules or engage in behavior that is illegal or harmful to other Web sites.

Privacy of Children
We are committed to protecting the privacy of children. This site is not intended, or designed to attract children under the age of eighteen.

Security Measures
The Web site has security measures in place, including the use of industry-standard secure socket layer encryption (SSL), to protect the confidentiality of any of Your Information that you volunteer. However, to take advantage of this, your browser must support encryption protection. Regardless of the precautions taken by you or by us, perfect security does not exist on the Internet. We cannot ensure or warrant the security of any information you transmit to us, and you transmit such information at your own risk.

Links to Other Sites
As a convenience to our visitors, the Web site currently contains links to a number of sites that we believe may offer useful information. This Privacy Policy does not apply to those sites. We suggest contacting those sites directly for information on their privacy policies.

Additional Information
The Web site is intended for use by United States residents only. Any personally identifiable information submitted at the Web site goes to Incyte in the United States and by submitting personally identifiable information to the Web site, you waive any rights you may have under any law of any other country or region.

Contact
If you have any comments or questions regarding our Privacy Policy, please contact us at support@incyte.com.

We may update this Privacy Policy from time to time. When we do update it, for your convenience, we will make the updated policy available on this page. This Privacy Policy was last updated November 2011.

INDICATIONS AND USAGE

Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post–polycythemia vera myelofibrosis and post–essential thrombocythemia myelofibrosis.

IMPORTANT SAFETY INFORMATION

• Treatment with Jakafi can cause hematologic adverse reactions, including thrombocytopenia, anemia and neutropenia, which are each dose-related effects, with the most frequent being thrombocytopenia and anemia. A complete blood count must be performed before initiating therapy with Jakafi. Complete blood counts should be monitored as clinically indicated and dosing adjusted as required
• The three most frequent non-hematologic adverse reactions were bruising, dizziness and headache
• Patients with platelet counts <200 X 109/L at the start of therapy are more likely to develop thrombocytopenia during treatment. Thrombocytopenia was generally reversible and was usually managed by reducing the dose or temporarily withholding Jakafi. If clinically indicated, platelet transfusions may be administered
• Patients developing anemia may require blood transfusions. Dose modifications of Jakafi for patients developing anemia may also be considered
• Neutropenia (ANC <0.5 X 109/L) was generally reversible and was managed by temporarily withholding Jakafi
• Patients should be assessed for the risk of developing serious bacterial, mycobacterial, fungal and viral infections. Active serious infections should have resolved before starting Jakafi. Physicians should carefully observe patients receiving Jakafi for signs and symptoms of infection (including herpes zoster) and initiate appropriate treatment promptly
• A dose modification is recommended when administering Jakafi with strong CYP3A4 inhibitors or in patients with renal or hepatic impairment [see Dosage and Administration]. Patients should be closely monitored and the dose titrated based on safety and efficacy
• There are no adequate and well-controlled studies of Jakafi in pregnant women. Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus
• Women taking Jakafi should not breast-feed. Discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother

Note: To view or print PDF files, you must have Adobe® Reader®. Download Adobe Reader here.

Adobe® Reader® is a registered trademark of Adobe Systems Incorporated.

By clicking third-party links, you are leaving an Incyte Web site and going to an external, entirely independent third-party Web site. Incyte provides these links as a service to its Web site visitors and users and takes no responsibility for any information presented on such sites or for your use of or access to such sites.